Sign in
CompletedNo phase

Clinical Applicability of pCASL as a Substitute for FDG-PET in MCI and SCD Patients

Key facts

Who runs it
University of Milano Bicocca
Where
Italy1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
150 people enrolled
Started
3 Jun 2022
Ended
1 Mar 2026
Type of study
Observational
Treatments tested
  • pCASL
Record updated
24 March 2026

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Patients with mild cognitive impairment or subjective cognitive decline according to established criteria
  • Clinical Dementia Rating scale of 0 or 0.5
  • Signed informed consent before study entry

Who cannot take part

  • Enrollment in anti-amyloid or anti-tau drugs trials
  • Known major neurological or psychiatric comorbidities
  • History of substance or alcohol abuse
  • Contraindication to brain MRI, FDG-PET or lumbar puncture
  • Secondary causes of cognitive decline
  • Known causes of cerebral brain perfusion alterations

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this observational study is to compare cerebral perfusion patterns with pseudo-continuous arterial spin labeling (pCASL) and brain metabolism patterns with fluorodeoxyglucose-position emission tomography (FDG-PET) in patients with mild cognitive impairment (MCI) and subjective cognitive decline (SCD). The main questions it aims to answer are:

Read full original descriptionShow less

* Do pCASL sequences identify hypoperfusion patterns that correlate well with FDG-PET hypometabolic patterns? * Are there differences in this correlation in terms of cerebrospinal fluid (CSF) profiles? * Can hypoperfusion patterns in pCASL predict conversion to dementia? Participants will undergo brain 3 Tesla magnetic resonance imaging (MRI), FDG-PET, lumbal puncture and blood collection to analyze amyloid beta and tau, yearly detailed neuropsychological tests for three years.

Treatments tested

  • pCASL

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Clinical Applicability of Pseudo-continuous Arterial Spin Labeling as a Substitute for FDG-position Emission Tomography in MCI and SCD Patients
Record updated
24 March 2026